Home > News > pSivida Limited Describes Strategy for Further Clinical Trials
February 18th, 2005
pSivida Limited Describes Strategy for Further Clinical Trials
Abstract:
Dr. Aston discusses the importance of the recently-announced successful Phase IIa clinical trials of the company's lead product, BrachySil(TM) for liver cancer, as well as the company's plans for clinical trials and commercialization of the product. In the most recent trial, it was demonstrated that BrachySil(TM) is safe and effective in tumor regression with increased efficacy.
Source:
businesswire
Bookmark:
| Related News Press |
Possible Futures
Spinel-type sulfide semiconductors to operate the next-generation LEDs and solar cells For solar-cell absorbers and green-LED source October 3rd, 2025
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||